Skip navigation

Examining Developing Therapies for Non-Addictive Solutions

March 12-13, 2019
  • Washington, DC

The opioid epidemic is prevalent in the news cycle and tops lists on both pharmaceutical and healthcare organizations as a critical problem to be solved. Addressing this expanding market is the latest event from CBI, Pharmaceutical Innovations for Pain Management. Born out of our success from previous events on Abuse-Deterrent Formulations, this conference is a continuation of dialogue on novel therapies that address the addiction crisis and effective management of pain.

The potential for a new pain medication to reach blockbuster status has never been greater. According to the World Health Organization, about 116 million Americans were living with chronic pain in 2011, and many pharmaceutical companies have sensed for years that more therapies are going to be needed and are hunting for new molecules to alleviate pain or looking into different pathways to block pain signals from reaching the brain. While progress has come in fits and starts, the regulatory environment is favorable for moving promising therapies down the pipeline. –PharmaPro, 02/2018

Topics for discussion will include:

  • New Chemical Entities
  • Innovations in Topical Ad Cannabis Therapies
  • Hurtles to Use
  • Transitioning From Opioid Focus Landscape
  • Disease-Focused Targeted Therapies
  • Genotyping for Specific Treatment
  • Targeted and Un-Targeted Therapies

Pharmaceutical Innovations for Pain Management

Examining Developing Therapies for Non-Addictive Solutions

The opioid epidemic is prevalent in the news cycle and tops lists on both pharmaceutical and healthcare organizations as a critical problem to be solved. Addressing this expanding market is the latest event from CBI, Pharmaceutical Innovations for Pain Management. Born out of our success from previous events on Abuse-Deterrent Formulations, this conference is a continuation of dialogue on novel therapies that address the addiction crisis and effective management of pain.

The potential for a new pain medication to reach blockbuster status has never been greater. According to the World Health Organization, about 116 million Americans were living with chronic pain in 2011, and many pharmaceutical companies have sensed for years that more therapies are going to be needed and are hunting for new molecules to alleviate pain or looking into different pathways to block pain signals from reaching the brain. While progress has come in fits and starts, the regulatory environment is favorable for moving promising therapies down the pipeline. –PharmaPro, 02/2018

Topics for discussion will include:

  • New Chemical Entities
  • Innovations in Topical Ad Cannabis Therapies
  • Hurtles to Use
  • Transitioning From Opioid Focus Landscape
  • Disease-Focused Targeted Therapies
  • Genotyping for Specific Treatment
  • Targeted and Un-Targeted Therapies